Weiss Ratings Reaffirms "Sell (D-)" Rating for Vor Biopharma (NASDAQ:VOR)

Key Points

• Weiss Ratings has reaffirmed a "Sell (D-)" rating for Vor Biopharma (NASDAQ:VOR), indicating continued lack of confidence in the company's stock performance.
• Vor Biopharma's stock has recently experienced a decline, trading down to $27.19 from a high of $65.80 within the past year, amid mixed ratings from various analysts.
• Insider selling activity has been notable, with major shareholders reducing their holdings by over 1.8 million shares in the last quarter, which reflects a potential lack of confidence from internal stakeholders.

Vor Biopharma (NASDAQ:VOR - Get Free Report)'s stock had its "sell (d-)" rating reiterated by equities researchers at Weiss Ratings in a research report issued on Friday,Weiss Ratings reports.

VOR has been the topic of a number of other research reports. Stifel Nicolaus upgraded Vor Biopharma from a "hold" rating to a "buy" rating and set a $55.00 target price on the stock in a research report on Wednesday, September 24th. Wall Street Zen downgraded Vor Biopharma to a "strong sell" rating in a research report on Saturday, June 28th. HC Wainwright restated a "buy" rating and issued a $60.00 target price on shares of Vor Biopharma in a research report on Thursday, August 14th. Robert W. Baird upgraded Vor Biopharma from a "neutral" rating to an "outperform" rating and lifted their target price for the company from $20.00 to $64.00 in a research report on Wednesday, October 15th. Finally, Baird R W upgraded Vor Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Vor Biopharma has a consensus rating of "Hold" and a consensus price target of $77.83.

Vor Biopharma Price Performance

NASDAQ VOR traded down $0.57 on Friday, reaching $27.19. 276,933 shares of the company were exchanged, compared to its average volume of 393,079. The firm has a fifty day simple moving average of $35.41. The company has a market cap of $186.25 million, a PE ratio of -0.10 and a beta of 2.07. Vor Biopharma has a fifty-two week low of $2.62 and a fifty-two week high of $65.80.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($43.60) earnings per share for the quarter, missing analysts' consensus estimates of ($11.40) by ($32.20).

Insider Buying and Selling at Vor Biopharma

In related news, major shareholder Reprogrammed Interchange Llc sold 11,616 shares of the business's stock in a transaction on Monday, October 20th. The stock was sold at an average price of $30.05, for a total value of $349,060.80. Following the sale, the insider owned 1,167,109 shares in the company, valued at approximately $35,071,625.45. The trade was a 0.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ra Capital Management, L.P. sold 25,027 shares of the business's stock in a transaction on Tuesday, October 21st. The shares were sold at an average price of $28.11, for a total value of $703,508.97. Following the completion of the sale, the director owned 1,401,226 shares in the company, valued at $39,388,462.86. This represents a 1.75% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,810,144 shares of company stock worth $45,516,074 in the last quarter. Company insiders own 0.45% of the company's stock.

Institutional Investors Weigh In On Vor Biopharma

Several institutional investors and hedge funds have recently modified their holdings of the company. Money Concepts Capital Corp raised its holdings in shares of Vor Biopharma by 106.1% in the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after buying an additional 26,535 shares during the period. XTX Topco Ltd purchased a new stake in shares of Vor Biopharma in the 2nd quarter valued at $66,000. Goldman Sachs Group Inc. grew its stake in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock worth $61,000 after purchasing an additional 58,247 shares in the last quarter. Ariose Capital Management Ltd acquired a new position in Vor Biopharma during the 3rd quarter worth $5,368,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in Vor Biopharma during the 1st quarter worth $100,000. Hedge funds and other institutional investors own 97.29% of the company's stock.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.